We turn the next generation of technologies into reality.

The Y Innovations Group leverages strategic consulting, venture capital, and innovation studios across the artificial intelligence, energy, and life sciences sectors.

Watch the strand open, then select a node
The Firm

Advisory and consulting for the companies building what is next.

The Firm is the advisory and consulting arm of Y Innovations Group. We work alongside founders, executives, and investors across artificial intelligence, biotechnology, and energy, pairing deep scientific and technical understanding with the commercial judgment to act on it. From corporate strategy and intellectual property to market and competitive intelligence, investment diligence, business development, and regulatory readiness, we help you make the decisions that shape the company.

Strategic Planning and Analysis Intellectual Property Strategy Market Research and Competitive Analysis Investment Analysis Business Development CMC, Quality, and Regulatory
Yung Ventures

Deep in artificial intelligence, biotechnology, and energy.

Yung Ventures is the group's venture capital arm, pursuing high-conviction, thesis-driven investments across life sciences and the energy transition. We combine the scientific and technical depth of our subject-matter experts with the market insight and operational experience of seasoned industry veterans, backing companies at the stages where that combination matters most.

0
Sectors: AI, biotech, energy
0
Practices under one roof
$0M+
Upfront deal specialization
Start a conversation

Tell us what you are building.

Reach us at operations@y-innovations.com, book a free introductory call, or use the form below.

Submitting opens a pre-filled message in your email app addressed to operations@y-innovations.com — nothing is sent until you send it.
Home / The Firm
Y INNOVATIONSGroup

The Firm at Y Innovations

Comprehensive life cycle advisory and consulting
Gold bull and bear on a chessboard before financial market displays
The Firm

The Firm provides comprehensive life cycle advisory and consulting services for companies in the artificial intelligence, energy, and life sciences sectors.

Our Services

Advisory across the full life cycle.

The Innovation on Demand Platform

Expertise, precisely when you need it.

Y Innovation's flexible Innovation on Demand Platform marks a transformative advancement in the realm of research and development. We want to democratize access to high-caliber scientific expertise. By offering access to a diverse pool of specialized talent on a per-project basis, our Innovation on Demand platform alleviates the financial and logistical burdens associated with full-time hires. Our pioneering approach allows organizations to engage leading experts and cutting-edge researchers precisely when needed, without long-term commitments.

The Firm

Put the full firm to work.

Life cycle advisory across AI, energy, and life sciences, from first strategy to regulatory approval.

Work with Us Return to the helix
Home / The Firm / Strategic Planning and Analysis

Strategic Planning and Analysis

Comprehensive corporate strategy for aggressive and sustainable growth

Strategy rooted in practicality and detailed analysis. We develop comprehensive strategies, weighing the most important factors, including intellectual property, resources, capabilities, and competition for both growth and early stage companies.

Strategic planning and analysis
Corporate Growth

Develop and adapt your strategy

We aim to work with you to craft a successful business strategy with an eye towards optimizing your resources, planning for success, optimizing contingency plans, and securing funding. Through a detailed analysis of your company in view of its competitors, the industry, market trends and a deep understanding of the company's technology and value proposition, we seek to provide valuable and comprehensive insights into core strengths to advance, competencies to build, and risks to mitigate.

Key Services

strategyGeneral corporate strategy
hubBuilding a synergistic and cohesive strategy between core functions
paymentsFinancing options and management of funding relationships and expectations
fact_checkDue diligence preparation
experimentResearch and development study planning
insightsMVP analysis
clinical_notesIndication selection
alt_routeClear guidelines for project go/no go decisions
trending_upScale-up strategy
account_balanceIPO and post-IPO considerations
Emerging Company Strategy

Purpose-built strategy for the earliest and most consequential stage

We are deeply rooted in the start-up community and understand the distinct pressures of building an early stage venture. The decisions made in these first chapters shape the company for years to come, from the science you pursue to the way you raise capital and structure your team. Emerging Company Strategy is our dedicated engagement for founders who need a partner to help translate a promising idea into a fundable, buildable company.

Rather than a generic playbook, we work alongside your leadership to set priorities, sequence the milestones that matter, and put the operational framework in place across your core functions. The goal is a company that can move quickly, spend deliberately, and stand up to the scrutiny of investors, partners, and future acquirers.

architecture

Foundational framework

We help you build the framework for key departments including research and development, legal, and corporate and business development, so the company is structured to scale from day one.

flag

Milestone sequencing

We define the value-creating milestones ahead and order them so each dollar and each quarter moves you toward proof points that de-risk the story for the next round.

payments

Fundraising readiness

We prepare you for capital conversations by sharpening the narrative, pressure-testing the plan, and organizing the diligence materials investors expect to see.

biotech

Indication and program focus

For science-led ventures, we help select the lead indication or application and shape a development plan that balances near-term validation with long-term platform value.

groups

Team and partner building

We advise on the early hires, advisors, and outside partners that give the company credibility and reach without adding avoidable cost.

verified_user

Risk and contingency planning

We map the risks that can derail an early venture and put clear contingencies and go or no-go thresholds in place before they are needed.

Start a conversationBack to Services
Home / The Firm / Intellectual Property Strategy
Strategic Asset Management

Intellectual Property Strategy

Intellectual property is the foundation on which we were originally founded. We know intellectual property can be expensive. We can help you be cost-effective. Our goal is to help you maximize your portfolio strategy through our deep knowledge built on years of experience litigating, prosecuting, and managing intellectual property portfolios as outside and in-house counsel.

Audit Your IP View Methodology
Macro shot of liquid gold droplets and bubbles forming an organic molecular lattice
Established Foundation
Executed Properly, Proactively Valuable
Service Fields

How we protect and monetize it.

Select a field to explore how we protect and monetize it. Executed properly, your intellectual property may be used to proactively increase your value and protect your ability to operate competitively.

experiment
experiment

Patents

What we deliver
    Case Studies

    Strategy, proven in the field.

    Real engagements where IP strategy became a value driver for our portfolio companies.

    01 · Biotech, Series B

    Building a high-value IP portfolio for a scaling biotech

    A mid-stage biotech company engaged the firm to transform a fragmented set of patent filings and trade secrets into a cohesive global IP strategy that would support fundraising, partnerships, and eventual exit. Over 12 months, the firm helped the client redesign its IP portfolio, close critical gaps, and position its assets as a core value driver in negotiations with investors and strategic partners.

    Sector
    Oncology-focused biotech developing novel therapeutic platforms
    Stage
    Series B, preparing for later-stage institutional funding and ex-US expansion
    The Challenge

    Rapid scientific progress had outpaced the company's IP strategy, leaving overlapping filings, geographic gaps, and unclear ownership of key know-how.

    Problem Statement
    verified
    Clarify ownership and protection
    Map patents, applications, trade secrets, software, and data rights to specific products and platforms.
    language
    Design a scalable global strategy
    Decide which inventions warrant international protection and where to rely on contractual protection.
    clinical_notes
    Make IP legible to investors
    Translate technical filings into a clear narrative for non-specialist business development teams.
    Our Approach
    search_insightsPhase 1
    Diagnostic and IP audit
    Conducted a full IP audit across patents, trademarks, copyrights, and licensing agreements to assess strength and business alignment.
    architecturePhase 2
    Portfolio redesign
    Grouped existing rights into clear technology families and prioritized filings around core high-value platforms.
    history_eduPhase 3
    Investor-grade story
    Created concise IP strategy documents and deal-ready artifacts including heatmaps and jurisdiction matrices.
    Process Execution · Key actions taken
    Structured IP audit
    Ran a structured IP audit, scoring each asset for strategic relevance, legal robustness, and commercial potential.
    Remedial filing plan
    Identified high-value inventions at risk and developed a remedial filing plan with specialist counsel to strengthen claims.
    Jurisdiction strategy
    Designed a jurisdiction strategy focused on core markets and future growth territories, balancing protection strength against cost.
    Invention capture
    Implemented processes for documenting new inventions and capturing data and software-related IP generated by R&D teams.
    Investor-facing IP brief
    Produced an investor-facing IP brief and visual portfolio map that integrated scientific, legal, and commercial perspectives.
    Tap a number, or let it play
    The Outcome · Results and impact
    hub
    Reorganized Portfolio
    Defined technology families, making it significantly easier for investors to diligence and value the assets.
    trending_up
    Premium Valuation
    Investor-grade materials used successfully in funding rounds; IP cited as core rationale for valuation.
    gavel
    Ongoing Governance
    Adopted recommended IP practices, reducing risk of unprotected innovations and improving cross-functional awareness.
    shield_person
    Stronger Protection
    Prosecution strategy strengthened protection around lead platforms, supporting partnering discussions.
    Y Innovations Group

    Secure your future discoveries.

    Let our expert team guide your intellectual property roadmap. We bridge the gap between scientific innovation and legal excellence.

    Consult With An Expert Back to Services
    Home / The Firm / Market Research and Competitive Analysis

    Market Research and Competitive Analysis

    Stay ahead of the competition with timely, detailed, and relevant competitive intelligence

    Actionable Intelligence

    With our wealth of industry experience, our goal is to understand your technology in incredible detail so that we may identify your main competitors and help you differentiate your business.

    We have extensive experience in advanced landscape analyses in the biotech and energy fields as well as other heavily government-regulated industries. Our services are unique and benefit from a keen understanding of the technology and field, but also a thorough understanding of the intellectual property landscape.

    Competitive Strength · Market Analysis

    What our competitive analysis covers

    Every engagement is built around four connected lenses. Read together, they show not only who you are competing against today, but where the market is heading and where your technology can win.

    01
    gavel

    Intellectual Property

    We read the patent estate as a strategic map, not a filing list. We show you where the crowded art sits, where freedom to operate is genuinely open, and how your protection compares to the field so you can invest and negotiate from a position of clarity.

    checkPatent landscape across competitors, assignees, and filing trends
    checkFreedom to operate and blocking-art exposure on your core claims
    checkWhite-space mapping to guide new filings and portfolio strategy
    02
    biotech

    Technical Landscape

    Because we understand the science in depth, we assess technologies on their merits rather than their marketing. We benchmark modalities, platforms, and approaches so you can see where your technical advantage is real and durable, and where it is at risk of being matched.

    checkModality and platform benchmarking against rival approaches
    checkDifferentiation on efficacy, safety, durability, and manufacturability
    checkTechnical risk and moat analysis as the field evolves
    03
    groups

    New and Incumbent Players

    We profile the full field, from entrenched incumbents to the early-stage entrants that can reshape a market overnight. You learn who holds share and why, who is gaining, and which emerging players deserve your attention as partners, threats, or acquisition targets.

    checkIncumbent share, strategy, and points of vulnerability
    checkEmerging entrants and disruptive clinical-stage programs
    checkPartnership, threat, and target assessment across the field
    04
    trending_up

    Market Trends

    We track where demand, capital, regulation, and standard of care are moving, so your strategy is built for the market that is arriving rather than the one that is passing. Trends are translated into concrete implications for your timing, positioning, and investment case.

    checkDemand, pricing, and reimbursement direction of travel
    checkRegulatory and standard-of-care shifts that reset the bar
    checkCapital and dealmaking signals shaping the competitive field

    Selected case studies

    How our market and competitive intelligence work translates into strategy. Flip through recent engagements.

    1 / 3
    Case Study · Cell Therapy

    Building a defensible market strategy for a next-generation cell therapy platform

    A rapidly developing cell therapy company engaged our team as it prepared to transition from platform validation into an indication-specific development strategy. The company had promising early science, but faced a familiar challenge: a crowded competitive landscape, evolving regulatory expectations, constrained capital markets, and uncertainty regarding the indication that would best support clinical, strategic, and financial differentiation. Our mandate was to translate a technically credible platform into a focused, investor-ready market strategy.

    Client
    Venture-backed cell therapy company
    Sector
    Oncology and regenerative medicine
    Engagement
    Market strategy, competitive intelligence, indication prioritization, and commercialization planning
    flagThe challenge

    The client's platform had potential applications across several oncology and immune-mediated disease settings. Each opportunity presented distinct tradeoffs:

    • arrow_rightUnmet clinical need and addressable patient population
    • arrow_rightStandard-of-care limitations and treatment sequencing
    • arrow_rightCompetitive density across approved therapies, clinical-stage programs, and emerging modalities
    • arrow_rightManufacturing complexity, cost of goods, and treatment-site requirements
    • arrow_rightRegulatory precedent and clinical-development feasibility
    • arrow_rightPotential for strategic partnerships, licensing, or acquisition interest

    The central question was not whether the platform could be applied broadly. It was where the company could establish the clearest path to differentiated clinical value and durable commercial relevance.

    routeOur approach

    We developed an integrated market and competitive strategy that connected scientific opportunity with commercial reality.

    low_priorityMarket and indication prioritization

    We evaluated prospective lead indications against a structured decision framework spanning patient population, current treatment pathway, outcomes gaps, reimbursement conditions, development timelines, and likely capital requirements. This produced a prioritized indication roadmap that balanced near-term clinical validation with longer-term platform expansion.

    radarCompetitive intelligence

    We mapped the therapeutic landscape across approved products, active clinical trials, discontinued programs, academic research, and adjacent modalities. The analysis showed where competitors were concentrated, where clinical endpoints were becoming more demanding, and where the client could credibly differentiate on efficacy, durability, safety, manufacturing, or accessibility.

    ads_clickPositioning and differentiation

    We worked with leadership to define a clear strategic position: not simply another cell therapy program, but a targeted solution to a defined limitation in the existing treatment paradigm. The resulting narrative supported scientific communications, investor materials, business-development outreach, and future clinical-site engagement.

    account_treeCommercialization scenario planning

    We developed market-entry scenarios reflecting different clinical-readout outcomes, manufacturing models, launch sequences, and partnership structures. This let management identify the early decisions that would preserve optionality while avoiding unnecessary spend before proof-of-concept data.

    insightsImpact

    The engagement gave the company a disciplined basis for clinical and corporate decision-making.

    • checkPrioritized a lead indication and sequenced expansion opportunities based on clinical need, competitive whitespace, and development feasibility
    • checkClarified the company's differentiated value proposition for investors, potential partners, and key opinion leaders
    • checkIdentified competitive risks early, including likely shifts in standard of care and crowded trial activity
    • checkStrengthened the development narrative by linking scientific novelty to a specific commercial and patient-value thesis
    • checkCreated a strategic framework that could be updated as clinical data, financing conditions, and competitor activity evolved
    Representative Outcome

    The client moved from a broad platform story to a focused development and partnering strategy, enabling leadership to allocate capital and technical resources toward the opportunities most likely to create strategic value.

    Our role: We help advanced-therapy companies make the difficult choices early: where to compete, how to differentiate, what evidence to generate, and how to build a credible path from promising science to market leadership. The firm's work in biotech includes cross-border analysis of private biotech funding, regulatory conditions, intellectual-property considerations, clinical-trial activity, biomanufacturing, and partnering dynamics.

    Case Study · Home Energy

    Building a growth engine for an emerging energy-efficiency company

    An early-stage home-energy services company engaged our team as it moved from founder-led sales and localized projects toward a scalable growth model. The company had strong technical capabilities and clear customer value, but needed to build the commercial infrastructure required to grow predictably across a competitive home-services market. Our mandate was to turn a high-potential operating business into a focused, repeatable growth platform.

    Client
    Early-stage SaaS home-services company
    Sector
    SaaS home energy efficiency
    Engagement
    Growth strategy, market positioning, customer acquisition, and service-line expansion
    flagThe growth challenge

    The company had demonstrated demand, but growth was constrained by the practical challenges common to early-stage home-services businesses:

    • arrow_rightCustomer acquisition depended on a limited number of channels and inconsistent referral flow
    • arrow_rightHomeowners often viewed energy efficiency as a one-time project rather than an ongoing home-performance relationship
    • arrow_rightThe company needed to communicate a differentiated value proposition beyond rebates, discounts, or individual equipment installations
    • arrow_rightService offerings, sales processes, scheduling, financing, and follow-up needed to operate as an integrated customer journey
    • arrow_rightManagement needed to decide which offerings, customer segments, and geographic areas warranted investment first

    The core question was how to build a scalable, profitable growth engine without losing the operational quality and local trust that had created the company's early traction.

    routeOur approach

    We developed an integrated growth strategy connecting market opportunity, customer economics, service design, and execution.

    groupCustomer and market segmentation

    We identified priority homeowner segments based on housing type, heating and cooling needs, energy burden, upgrade readiness, local incentive eligibility, and potential lifetime value. This enabled the company to focus its sales and marketing resources on the customers most likely to purchase, refer, and return for additional services.

    ads_clickPositioning and demand generation

    We repositioned the company from a provider of contractor matching for isolated energy upgrades to a trusted whole-home performance partner. The refined message centered on tangible homeowner outcomes: lower utility costs, greater year-round comfort, improved indoor-air quality, and reliable equipment.

    hubAcquisition-channel strategy

    We designed a diversified customer-acquisition plan spanning direct digital marketing, referral partnerships, community relationships, affiliate programs, real-estate and property-management relationships, and strategic partnerships. The strategy reduced dependence on any single lead source and created measurable pathways from awareness to booked assessment, completed project, and repeat engagement.

    dashboard_customizeService-line and revenue design

    We developed a service portfolio that linked the various services, creating clear cross-sell opportunities and increasing customer lifetime value while helping smooth seasonal revenue variability.

    account_treeOperating model for scale

    We mapped the end-to-end customer journey, from first inquiry through project completion and post-installation follow-up. The resulting growth plan identified the processes, metrics, staffing priorities, technology tools, and quality controls needed to scale without sacrificing conversion, customer satisfaction, or project margins.

    checklistStrategic deliverables

    The engagement provided management with a practical growth blueprint, including:

    • checkA prioritized customer-segment and geographic-expansion strategy
    • checkA differentiated market position, new website, and backend software
    • checkA customer-acquisition plan with channel-level metrics and conversion targets
    • checkA service-bundling framework to grow average revenue per customer and recurring revenue
    • checkA sales-funnel and customer-journey design, from initial lead through repeat service
    • checkA growth dashboard covering lead quality, booking rate, close rate, project margin, customer-acquisition cost, referral rate, and lifetime value
    • checkA phased plan for hiring, partner development, systems implementation, and expansion
    insightsImpact

    The company gained a clear path from early traction to scalable commercial growth.

    • checkFocused growth investment on the highest-value customer segments and most productive acquisition channels
    • checkCreated a compelling market position distinct from both commodity contractors and rebate-only providers
    • checkEstablished a service model designed to increase average project value, repeat business, and customer referrals
    • checkBuilt a more predictable framework for measuring marketing efficiency, sales performance, project economics, and expansion readiness
    • checkPositioned the business to participate effectively in the growing market for home electrification, efficiency upgrades, preventive maintenance, and climate-resilient housing

    Our role: We help emerging companies build the growth systems that turn technical expertise into repeatable revenue, durable customer relationships, and a defensible market position.

    Case Study · Fintech

    Defining a differentiated fintech investment case

    An early-stage fintech company engaged our team as it prepared to raise institutional capital. The company had built a technically sophisticated product designed to improve a complex financial workflow, but it faced a common financing challenge: its strongest differentiators were difficult to explain quickly to non-technical investors.

    The company did not need a more elaborate product description. It needed a market-backed investment narrative that demonstrated why its technology mattered, how it compared with alternatives, and why its approach could produce a measurably better user experience and more defensible business model.

    Client
    Early-stage fintech company
    Sector
    Financial technology and digital infrastructure
    Engagement
    Market research, competitive intelligence, technical positioning, investor materials, and financing preparation
    flagThe challenge

    The fintech market was crowded with companies making similar claims around speed, automation, access, intelligence, and improved financial outcomes. While the client's platform offered meaningful technical advantages, investors needed clear answers to fundamental commercial questions:

    • arrow_rightWhat specific market problem did the company solve more effectively than incumbent systems and emerging fintech competitors?
    • arrow_rightWhich aspects of the product architecture created a genuine competitive advantage rather than a feature-level distinction?
    • arrow_rightHow did technical decisions affect onboarding, transaction flow, reliability, compliance, security, customer support, and the end-user experience?
    • arrow_rightWhere could the company establish durable differentiation as competing platforms evolved?
    • arrow_rightHow could management explain complex technical concepts without requiring investors to understand the underlying infrastructure in detail?

    The central task was to turn technical sophistication into a clear, credible, and investable market position.

    routeOur approach

    We developed a research-led competitive strategy that connected the company's technical architecture to market demand, user value, and investor relevance.

    travel_exploreMarket research and category definition

    We analyzed the company's target customer segments, buyer needs, existing workflows, industry pain points, adoption barriers, and broader market dynamics. This enabled the company to define its category with greater precision and demonstrate why current solutions were insufficient for a meaningful portion of the market.

    radarCompetitive intelligence

    We mapped the competitive landscape across incumbent financial-services providers, direct fintech competitors, adjacent software platforms, internal customer workarounds, and emerging technology entrants. The analysis went beyond basic feature comparisons to assess product architecture, workflow design, integration requirements, pricing logic, target customers, go-to-market strategies, compliance posture, and likely sources of competitive advantage. This work distinguished between companies that appeared similar at a high level and companies that posed a genuine competitive threat.

    psychologyExpert-informed technical analysis

    We incorporated perspectives from relevant technical, financial-services, product, and market experts to test the company's assumptions and evaluate its technical claims in real operating context. These consultations helped identify where the platform's architecture could reduce friction, improve data flow, strengthen reliability, shorten implementation time, or simplify a complex user journey. The resulting analysis focused on the practical commercial implications of the technology, not technical novelty for its own sake.

    touch_appUser-experience translation

    We assessed how the company's technical design could improve the experience of customers and end users. Rather than describing infrastructure in isolation, we showed how technical choices could support faster onboarding, fewer manual steps, more intuitive workflows, improved accuracy, reduced operational burden, and a smoother path from customer intent to completed financial action. This created a direct line between the product's technical foundation and the outcomes investors care about: adoption, retention, scalability, lower service costs, and defensibility.

    menu_bookInvestor narrative and materials

    We translated the findings into investor-ready materials that made the technical and competitive case understandable to a non-technical audience. The revised narrative explained the product through a simple progression:

    1. The market problem and why it remains unresolved
    2. The limitations of incumbent and competing approaches
    3. The company's technical and product-level distinction
    4. The user-experience and business-model implications of that distinction
    5. The evidence supporting the company's ability to win and scale
    checklistStrategic deliverables

    The engagement provided the company with an integrated market-intelligence and financing platform:

    • checkMarket landscape and customer-segment analysis
    • checkCompetitive intelligence map covering direct, indirect, incumbent, and emerging competitors
    • checkDifferentiation framework linking technical capabilities to customer and commercial outcomes
    • checkExpert-informed assessment of technical claims, implementation requirements, and user-experience implications
    • checkInvestor-ready explanation of the platform's architecture and technical advantage
    • checkRefined pitch deck, executive summary, market-sizing narrative, and competitive-positioning materials
    • checkDiligence-ready research files and supporting materials for the company's data room
    • checkInvestor talking points and responses to anticipated questions regarding competition, technical defensibility, user adoption, and scalability
    insightsImpact

    The company entered investor conversations with a more precise, evidence-based explanation of why it could win.

    • checkReframed the company from a technically complex product into a differentiated solution to a clearly defined market problem
    • checkDemonstrated how product architecture could improve the user experience and create commercially relevant advantages
    • checkDistinguished meaningful competitive advantages from generic fintech claims and feature comparisons
    • checkEquipped management to explain technical concepts in plain language without oversimplifying the company's differentiation
    • checkImproved alignment between the company's market research, competitive analysis, investor materials, and diligence package
    • checkEnabled founders to address investor questions about competition, adoption, scalability, and defensibility with greater credibility and precision

    Our role: We help fintech companies convert technical complexity into a market-backed investment case, showing investors not only what the technology does, but why it matters, for whom it matters, and why competitors will have difficulty replicating the advantage.

    Start a conversationBack to Services
    Home / The Firm / Investment Analysis

    Investment Analysis

    Support your investment with detailed and reliable diligence

    We have extensive experience in the AI, biotech, and energy industries who can support your technical and competitive intelligence analyses for your potential investments.

    Our services encompass company and MVP analyses, pipeline evaluation, as well as detailed industry and field landscape reports specifically tailored to your needs. Our analyses and reports are concise and digestible, without additional fluff.

    Investment analysis

    Key Areas of Investment Analysis

    Our diligence work concentrates on the two areas where technical judgment moves the deal: evaluating acquisition targets and weighing litigation exposure. Each engagement is scoped to your thesis and delivered as a concise, decision-ready read.

    M&A Target Analysis

    search_insights

    Target Screening

    Example: Building a ranked shortlist of acquisition candidates for a mid-cap pharma seeking oncology assets.

    travel_exploreLandscape sweepUniverse of private and public targets mapped by technology, stage, and geography.
    join_innerStrategic fitCandidates scored against portfolio gaps, therapeutic focus, and platform synergies.
    monitoringFinancial screenRevenue quality, burn, and capital needs assessed for deal feasibility.
    historyOwnership and deal historyCap table, prior rounds, and previous partnering activity reviewed.
    query_stats

    Target Deep-Dive

    Example: Full technical and commercial diligence on the lead candidate before a term sheet.

    biotechTechnology assessmentCore assets and underlying data quality evaluated by subject-matter experts.
    gavelIP positionPatent coverage, freedom to operate, and encumbrances verified.
    storefrontMarket and competitionAddressable market and competitive pressure quantified for the lead programs.
    account_treeIntegration riskPeople, systems, and manufacturing overlaps flagged before close.
    calculate

    Valuation and Synergies

    Example: Supporting the deal team on price, structure, and synergy targets.

    paymentsRisk-adjusted valuationScenario-based models spanning base, upside, and downside cases.
    mergeSynergy quantificationCost and revenue synergies estimated with realistic realization timelines.
    handshakeDeal structure optionsUpfront, milestones, and royalties balanced against risk allocation.
    flagPost-close roadmapFirst-100-day priorities defined to protect the key value drivers.

    Litigation Analysis

    balance

    Case Merits Assessment

    Example: Assessing patent-infringement exposure for a target with active litigation.

    gavelClaims and defensesStrength of asserted claims and available defenses evaluated with counsel.
    manage_searchPrior art and validityInvalidity risk gauged through targeted prior-art searching.
    request_quoteDamages exposureRealistic ranges modeled from comparable verdicts and settlements.
    scheduleTimeline and venueCourt, judge, and docket pace factored into the timing of risk.
    map

    Litigation Landscape

    Example: Mapping the dispute history of a sector before an investment or market entry.

    history_eduParty historyLitigiousness of key competitors and non-practicing-entity activity profiled.
    query_statsOutcome patternsWin rates and settlement behavior analyzed across venues and claim types.
    policyRegulatory overlaysParallel proceedings such as IPRs, ITC actions, and agency reviews tracked.
    account_balance

    Impact on Deal Value

    Example: Translating litigation risk into concrete transaction terms.

    functionsExposure quantificationProbability-weighted outcomes reduced to an expected cost range.
    verified_userDeal protectionsIndemnities, escrows, and insurance options recommended to offset risk.
    alt_routeGo/no-go framingClear thresholds defined for proceeding, renegotiating, or walking away.
    Start a conversationBack to Services
    Home / The Firm / Business Development
    Business Development

    We make deals.

    Organic growth through high-value strategic deals can be the difference between struggling for funding in a tough economic market and continuing strong operations and maintaining steady growth.

    Initiate Collaboration Back to Services
    Golden wireframe handshake
    Total Deal Scale

    Organic growth through high-value strategic deals, sourced, structured, and closed.

    Y Innovations focuses on business development transactions greater than $50M in upfront payment, totaling $750M to over $1B in aggregate milestones and royalties. The reason it works is simple: active engagement from first conversation through close, and long term planning that keeps the deal delivering long after signing.

    $50M+
    Targeted upfront payment where data quality and competitive tension support material immediate value.
    $750M–1B+
    Aggregate milestone and royalty opportunity across development, regulatory, and commercial economics.
    Global
    Structured counterparty process across pharmaceutical, biotechnology, and strategic partners.
    Why Y Innovations

    Where science, capital, strategy, and transaction execution meet.

    Rather than treating business development as a discrete outreach exercise, we build the strategic infrastructure required to make a company legible, compelling, and actionable to sophisticated counterparties. Our team supports clients from opportunity definition through negotiation, helping management teams:

    arrow_rightConvert differentiated science into a partner-ready value proposition.
    arrow_rightIdentify and prioritize the counterparties most likely to pay for strategic fit.
    arrow_rightAnticipate diligence barriers before they disrupt a process.
    arrow_rightPosition IP, data, market access, manufacturing, and development plans as transaction drivers.
    arrow_rightDesign deal structures that balance immediate financing needs with long-term enterprise value.
    arrow_rightMaintain executive-level control through diligence, negotiation, and closing.

    We help companies pursue the transactions that can define their next stage of growth: high-conviction deals with meaningful upfront value and durable economic upside.

    Strategic partnership pathway
    • checkA structured global counterparty process across pharmaceutical and biotechnology partners.
    • checkAn investment-grade package integrating scientific data, market intelligence, IP strategy, and commercial rationale.
    • checkClear negotiation positions on economics, territory, governance, development obligations, and retained platform rights.
    • checkA process designed to preserve value through parallel discussions and disciplined transaction sequencing.

    Y Innovations has been recognized for its capability to move early scientific concepts toward world-class therapeutics and maximize exits through strategic business development.

    Our Differentiator

    Active engagement is what sets the process apart.

    We do not hand a company a target list and step back. We engage directly in defining the deal, shaping the narrative, and carrying it through negotiation. That engagement rests on three advantages the largest counterparties recognize and respond to.

    corporate_fare

    Expertise from the buy side

    Our team brings first-hand expertise from the large business development targets our clients want to reach. We know how sophisticated pharmaceutical and strategic partners evaluate an opportunity, where they apply scrutiny, and what moves a deal to the top of their priority list.

    diversity_3

    Relationships that matter

    Deals move on trust and access. We hold strong, direct relationships with the decision-makers who actually sign transactions, so a client's opportunity reaches the right people rather than a general inbox, and reaches them with credibility already established.

    workspace_premium

    A track record with relevant parties

    Our strength is a proven track record of closing high-value deals with the specific counterparties that matter for each mandate. That history gives our positions weight at the table and gives counterparties confidence that the process will be run to completion.

    The Deal Process

    From first conversation to lasting value.

    A successful deal process is built well before the first partner meeting. Select a stage to see how we run it.

    travel_explore
    Stage 01

    Strategic Sourcing

    We have extensive experience sourcing high-value deals and mapping the counterparties most likely to pay for strategic fit. We build a structured view of global pharmaceutical, biotechnology, and strategic partners based on therapeutic priorities, modality fit, internal pipeline gaps, geographic objectives, deal history, and capability needs.

    • arrow_rightGlobal counterparty landscape mapped to the asset and its optionality.
    • arrow_rightPrioritization by strategic fit, pipeline gaps, and demonstrated deal appetite.
    • arrow_rightDirect access to decision-makers through established relationships.
    Case Studies

    Scientific value, turned into strategic demand.

    How our business development work translates into competitive processes and durable economics. Flip through recent engagements.

    1 / 2
    Business Development Case Study

    From scientific value to strategic demand

    A venture-backed life sciences company had built a differentiated AI drug discovery platform with compelling preclinical evidence, a developing intellectual-property position, and potential applicability across multiple therapeutic programs. The company needed more than introductions to potential partners: it required a disciplined transaction strategy capable of translating technical value into a credible, competitive partnering process. Y Innovations was engaged to define the commercial narrative, identify the highest-value counterparties, prepare the company for rigorous diligence, and run a process positioned to secure both meaningful near-term capital and long-term asset value.

    Client
    Venture-backed biotechnology company with an AI drug discovery platform and multiple partnering pathways
    Objective
    Secure a strategic partnership that recognized platform value, protected optionality, and created a path to significant upfront economics and total potential value
    Our Role
    End-to-end business development strategy, transaction preparation, counterparty engagement, diligence coordination, deal-structure analysis, and negotiation support
    routeOur approach

    Y Innovations begins with the premise that a successful deal process is built well before the first partner meeting. We integrate commercial strategy, scientific diligence, competitive intelligence, intellectual-property positioning, and financial structuring into a single transaction thesis.

    insightsAsset and platform positioning

    Defined the differentiated scientific, clinical, technical, and IP elements most likely to drive strategic buyer interest and premium valuation.

    travel_explorePartner landscape development

    Mapped global pharmaceutical, biotechnology, and strategic counterparties based on therapeutic priorities, modality fit, internal pipeline gaps, geographic objectives, deal history, and capability needs.

    ads_clickTransaction narrative

    Reframed complex scientific data into a clear strategic proposition connecting the asset to the counterparty's portfolio, patient population, market opportunity, and development objectives.

    fact_checkDiligence readiness

    Prepared materials, data-room priorities, management messaging, and responses to anticipated scientific, technical, commercial, IP, and regulatory questions.

    query_statsCompetitive process management

    Sequenced outreach and discussions to create momentum, preserve negotiating leverage, and encourage parallel evaluation by qualified strategic parties.

    architectureDeal architecture

    Evaluated upfront payments, research funding, development and regulatory milestones, sales milestones, tiered royalties, option structures, territory allocations, co-development rights, governance, and retained economics.

    This integrated model reflects Y Innovations' broader ecosystem, which combines strategic consulting, venture capital, and innovation studios across biotechnology, AI, and energy finance.

    insightsValue creation

    The engagement was structured around maximizing risk-adjusted transaction value, not simply completing a deal. We helped the company identify which elements of value should be recognized upfront, which should be protected through milestone design, and which future rights should remain available for follow-on financing, additional indications, geographic partnerships, or platform expansion. The resulting deal strategy was calibrated for transactions featuring:

    • paymentsUpfront consideration. Targeting $50 million or more where data quality, strategic fit, and competitive tension support material immediate value.
    • trending_upDevelopment economics. Meaningful milestones tied to program initiation, clinical progress, registration, and approval.
    • storeCommercial economics. Sales-based milestones and tiered royalty participation aligned with long-term product potential.
    • tunePlatform optionality. Retained rights in selected indications, territories, targets, or next-generation applications where appropriate.
    • gavelGovernance. Decision rights, development oversight, information access, and escalation mechanisms that protect the client's position.
    • boltProcess leverage. A credible, data-backed process that gives counterparties a compelling reason to move decisively.
    Business Development Case Study

    From vaccine innovation to government supply partner

    A venture-backed vaccine platform company had advanced a differentiated prophylactic and therapeutic vaccine technology with strong preclinical data, initial clinical planning, and an expanding intellectual-property position. The company saw clear scientific demand across infectious disease and pandemic-preparedness programs, but lacked a systematic path into government procurement channels where the largest, most durable opportunities reside. It needed a disciplined government-tender strategy that could translate technical value into recurring, large-scale supply relationships. Y Innovations was engaged to build the government-facing commercial narrative, map and analyze relevant tenders, develop relationships with key decision-makers, and align manufacturing capacity to credibly deliver on awarded contracts.

    Client
    Venture-backed vaccine developer with a proprietary platform, multiple candidate programs, and flexible manufacturing options
    Objective
    Secure multi-year government supply agreements by winning competitive tenders while preserving platform and geographic optionality
    Our Role
    End-to-end government business development: tender intelligence, stakeholder mapping, bid strategy, manufacturing and supply alignment, and negotiation support
    routeOur approach

    Successful participation in government tenders is a process, not a one-off event. The work integrated policy awareness, procurement intelligence, technical positioning, and operational readiness into a single government-facing commercial thesis.

    travel_exploreTender landscape and intelligence

    Built a structured view of national and multilateral tenders across target regions, including qualification criteria, evaluation frameworks, historic award patterns, and key decision bodies.

    diversity_3Stakeholder and relationship strategy

    Prioritized health ministry officials, procurement agencies, public health institutes, and multilateral organizations, then built a relationship calendar of technical briefings, advisory engagement, and early positioning ahead of formal RFPs.

    campaignGovernment-focused value narrative

    Reframed the platform's scientific features into policy-relevant outcomes: health-system impact, surge capacity, pricing predictability, and alignment with national preparedness and local manufacturing objectives.

    descriptionBid design and submission readiness

    Defined bid templates, technical dossiers, quality and regulatory documentation, and pricing structures tailored to framework agreements, emergency procurements, and stockpile contracts.

    precision_manufacturingManufacturing and supply anchoring

    Aligned internal capacity and external CDMO and CMO partners with projected tender volumes and delivery timelines, so awarded tenders could be fulfilled reliably and at scale.

    query_statsProcess and leverage management

    Sequenced participation across multiple tenders to build track record, use early wins as validation in later bids, and maintain leverage on price, volume, and technology-transfer provisions.

    military_techFrom tender intelligence to awarded supply

    The engagement converted tender visibility and relationships into durable, risk-adjusted revenue streams rather than chasing isolated awards. Pre-tender positioning established the platform as a credible solution before formal RFPs through non-promotional technical briefings, expert consultations, and responses to requests for information. Strategic bid selection focused on tenders where technical fit, manufacturing readiness, geopolitical alignment, and budget scale supported attractive unit economics and multi-year renewals. Commercial and legal architecture structured pricing tiers, volume commitments, delivery schedules, and technology-transfer or local-fill options that balanced competitiveness with protection of core IP. Early awards with smaller or regional buyers demonstrated on-time delivery, quality performance, and pharmacovigilance maturity, strengthening future bids with larger national and multilateral buyers.

    insightsValue creation and strategic optionality
    • event_repeatRevenue profile. Tenders with potential to convert into multi-year framework agreements, stockpile arrangements, or renewal options that anchor a predictable revenue base.
    • factoryManufacturing leverage. Volumes and timelines negotiated to optimize existing assets and strengthen the case for incremental capacity or regional hubs.
    • publicPlatform and geographic rights. Flexibility preserved to deploy the platform into additional indications, private markets, and non-overlapping geographies.
    • verifiedStrategic credibility. Established the company as a capable government supplier, enhancing its attractiveness to larger manufacturers and strategic partners.

    Subscribe to our newsletter to stay up to date!

    Sign up with your email address.

    security Goes straight to us — no third-party mailing service
    Submitting opens a pre-filled message in your email app. We respect your privacy and you can unsubscribe at any time.
    Business Development

    Ready to close your next deal?

    Bring us the opportunity. We source, structure, and negotiate, then stay engaged long after the ink dries.

    handshake Deals over $50M upfront timeline Sourcing through close groups Partners for the long term
    Home / The Firm / CMC, Quality, and Regulatory

    CMC, Quality, and Regulatory

    Guidance to ensure safety and compliance
    Golden DNA helixLife Sciences

    We are your strategic partners for CMC

    Our experienced CMC Advisors and Consultants help you establish a robust clinical process to support your candidate through different phases of clinical development. Our experts assess, establish and improve functions like process development, analytical development, manufacturing, quality control, quality assurance and supply chain to meet operational and regulatory needs of your candidate.

    We are partnered with some of the largest and most reliable CROs and CDMOs in the industry, saving you time and money. We help design studies and generate Module 3 content for your regulatory submissions with support from our partners.

    Consulting and Advisory Menu

    Start a conversationBack to Services
    Home / The Firm / Research on Demand

    Research on Demand

    Maximize runway. Minimize overhead.
    Laboratory glassware ready for on-demand research
    Choose your field:
    mRNAPeptidesAntibodiesSmall MoleculesLipid NanoparticlesRecombinant ProteinsPlasmid DNAAssay DevelopmentCell LinesGene EditingVaccine CandidatesMonoclonal AntibodiesOligonucleotidesFormulationPharmacokineticsImmunoassaysBioconjugationProtein ExpressionIn Vitro ModelsToxicology ScreeningmRNAPeptidesAntibodiesSmall MoleculesLipid NanoparticlesRecombinant ProteinsPlasmid DNAAssay DevelopmentCell LinesGene EditingVaccine CandidatesMonoclonal AntibodiesOligonucleotidesFormulationPharmacokineticsImmunoassaysBioconjugationProtein ExpressionIn Vitro ModelsToxicology Screening

    YI Scientific Staff - From design to execution.

    Industry-trained scientists, engineers, and expert thought leaders at your fingertips with customizable and flexible arrangements, including hourly, daily, or longer term contracts. No matter the stage of your company, cost efficient and knowledgeable scientific teams are always a good investment.

    Experts from Leading Industry Institutions

    Leverage flexible, trained experts to run your experiments

    With our flexible Research on Demand program, you can work with industry-trained scientists, engineers, and expert thought leaders on all your needs from subject matter expert advisory work to virtual or in-person scientific research. Please contact us to book in-person research or book a free consultation. If you are not sure, please book a free consultation using the General Introductory Call booking.

    Example Engagements
    biotech
    Preclinical Scientist · In Vitro

    mRNA & Antibody Characterization

    Brief 01 / 04
    Engagement: 6–10 weeks
    Mode: In-person lab
    Client
    Seed-stage biotech advancing an mRNA-encoded antibody with no in-house wet-lab capacity or dedicated protein sciences staff.
    Objective
    Confirm construct expression, binding, potency, and early developability so leadership can commit to a single lead candidate with confidence.
    YI Staff & Contributions
    A YI molecular biologist designs the construct panel and optimizes transfection and expression; a YI protein sciences specialist characterizes binding kinetics and biophysical stability by ELISA/SPR; a YI assay development scientist builds and qualifies the cell-based potency and neutralization readouts; a YI study lead compiles the data into a lead-selection memo.
    Deliverables
    • scienceConstruct panel with optimized expression & transfection
    • timelineELISA / SPR binding affinity, kinetics & stability
    • coronavirusQualified cell-based potency & neutralization assays
    • descriptionDevelopability flags and lead-selection memo
    savings
    Why Research on Demand vs. a Full-Time Hire
    This campaign needs three distinct skill sets, molecular biology, protein science, and assay development, but each for only a few weeks. Recruiting and onboarding a single full-time scientist would take months of runway, cover just one of those disciplines, and sit idle once the reads are complete. Research on Demand supplies exactly the right specialists for the exact weeks they add value.
    pest_control
    Preclinical Scientist · In Vivo

    Humanized CD34+ NSG Tumor Study

    Brief 02 / 04
    Engagement: 12–20 weeks
    Mode: In-person vivarium
    Client
    Immuno-oncology group needing an efficacy readout for a candidate that depends on engaging a human immune system.
    Objective
    Demonstrate anti-tumor activity and immune engagement in a humanized model, with data robust enough to anchor a partnering discussion.
    YI Staff & Contributions
    A YI in vivo pharmacologist designs the study, defines cohorts, and sets dosing; a YI biostatistician powers the design and randomization; a YI vivarium-trained scientist manages engraftment, dosing, and tumor and body-weight monitoring; a YI flow cytometry specialist runs immune profiling and PK/PD sampling.
    Deliverables
    • groupsHumanization & engraftment verification
    • straightenPowered study design and dosing schema
    • monitoringTumor volume, survival, and body-weight curves
    • bloodtypeFlow-based immune profiling and PK/PD
    savings
    Why Research on Demand vs. a Full-Time Hire
    Humanized in vivo work is episodic, a program may run one or two of these studies a year. Carrying a permanent in vivo pharmacologist, statistician, and flow specialist between studies is costly and hard to justify. Research on Demand assembles a credentialed in vivo team only for the study window, so you pay for expertise while it is producing data, not while it waits for the next protocol.
    vaccines
    Preclinical Scientist · Study Design

    NHP Immunogenicity Study Design

    Brief 03 / 04
    Engagement: 4–8 weeks
    Mode: Advisory / remote
    Client
    Vaccine developer preparing for IND-enabling work without an internal nonclinical study lead or regulatory strategist.
    Objective
    Produce a defensible NHP immunogenicity study design that will withstand regulatory and CRO scrutiny and de-risk the IND path.
    YI Staff & Contributions
    A YI nonclinical study director authors the study design and protocol; a YI immunologist defines immunogenicity endpoints and the assay plan; a YI regulatory advisor aligns the design to IND expectations; a YI biostatistician sizes cohorts and the analysis plan; the team then supports CRO selection and defends the design in review.
    Deliverables
    • draftDose, route, and schedule rationale
    • checklistImmunogenicity endpoints and assay plan
    • handshakeCRO evaluation and protocol review
    • gavelRegulatory-ready design justification
    savings
    Why Research on Demand vs. a Full-Time Hire
    This is a weeks-long burst of senior judgment, study director, immunologist, and regulatory input, not a role that stays busy year-round at an early company. Hiring at that seniority is slow and expensive. Research on Demand delivers a regulator-ready design in a matter of weeks by bringing proven experts to the problem exactly when the IND timeline demands it.
    engineering
    Biomedical Engineer

    Device Feasibility & Bench Validation

    Brief 04 / 04
    Engagement: 8–14 weeks
    Mode: Hybrid
    Client
    Startup translating a benchtop prototype toward a testable device without in-house engineering, test, or regulatory staff.
    Objective
    De-risk the design and generate bench data that supports the next funding and regulatory milestone.
    YI Staff & Contributions
    A YI biomedical/design engineer leads design-for-manufacture review and requirements tracing; a YI test engineer builds the verification plan and executes bench testing; a YI QA/regulatory specialist maps results to applicable standards and drafts the risk documentation, giving the founder an integrated engineering function on demand.
    Deliverables
    • architectureDesign review and requirements trace
    • buildPrototype iteration and DFM guidance
    • experimentBench verification and test reports
    • verifiedStandards mapping and risk documentation
    savings
    Why Research on Demand vs. a Full-Time Hire
    Device programs move in phases that each call for a different engineering discipline, mechanical design, then test, then QA and regulatory. A single full-time hire cannot cover all three, and staffing all three permanently is unaffordable pre-revenue. Research on Demand flexes the exact mix each phase needs, compressing time-to-data without adding fixed headcount.
    The Cost Case
    biotech
    Preclinical Scientist · In Vitro

    mRNA & Antibody Work: Hire vs. On-Demand

    Model 01 / 04
    Basis: first year
    6–10 wk project
    First-year cost: hire vs. engagement
    $155,000 $48,000 In-house (yr 1) YI On-Demand
    In-house (yr 1)$155,000
    YI on-demand$48,000
    You save$107,000 · 69%
    Cumulative savings over year one
    $107,000 saved Month 1 Month 12

    infoOne FTE (~$120K base loaded) covers a single discipline; the on-demand engagement delivers molecular biology, protein science, and assay development for the weeks each is needed.

    pest_control
    Preclinical Scientist · In Vivo

    Humanized Tumor Study: Hire vs. On-Demand

    Model 02 / 04
    Basis: first year
    12–20 wk study
    First-year cost: hire vs. engagement
    $175,000 $85,000 In-house (yr 1) YI On-Demand
    In-house (yr 1)$175,000
    YI on-demand$85,000
    You save$90,000 · 51%
    Cumulative savings over year one
    $90,000 saved Month 1 Month 12

    infoA full-time in vivo scientist (~$132K base loaded) sits idle between episodic studies; on-demand supplies the in vivo lead, statistician, and flow specialist only for the study window.

    vaccines
    Preclinical Scientist · Study Design

    NHP Study Design: Hire vs. On-Demand

    Model 03 / 04
    Basis: first year
    4–8 wk advisory
    First-year cost: hire vs. engagement
    $235,000 $28,000 In-house (yr 1) YI On-Demand
    In-house (yr 1)$235,000
    YI on-demand$28,000
    You save$207,000 · 88%
    Cumulative savings over year one
    $207,000 saved Month 1 Month 12

    infoA senior nonclinical study director (~$180K base loaded) is a weeks-long need, not a year-round role; on-demand provides that seniority for the design phase alone.

    engineering
    Biomedical Engineer

    Device Feasibility: Hire vs. On-Demand

    Model 04 / 04
    Basis: first year
    8–14 wk project
    First-year cost: hire vs. engagement
    $150,000 $52,000 In-house (yr 1) YI On-Demand
    In-house (yr 1)$150,000
    YI on-demand$52,000
    You save$98,000 · 65%
    Cumulative savings over year one
    $98,000 saved Month 1 Month 12

    infoA full-time biomedical engineer (~$115K base loaded) covers one discipline; on-demand flexes design, test, and QA/regulatory across the project phases.

    Illustrative estimates for US venture-backed biotech in loaded terms (base salary plus benefits). “In-house (yr 1)” reflects the reality that a time-boxed project still requires a permanent hire, whose salary continues after the work is done; engagement fees are one-time. Figures exclude recruiting, onboarding, and idle capacity, which raise the true cost of hiring. Actual costs vary by stage, location, and scope.

    Procurement, Handled

    We source and buy so your study never waits

    Y Innovations handles procurement for every Research on Demand study. We maintain close, ongoing relationships with multiple suppliers across the US and select other countries, and our sourcing is global, so reagents, models, consumables, and instrument time are secured through vetted channels while you stay focused on the science.

    schedule

    Weeks off the timeline

    Established vendor accounts and standing relationships mean no new-supplier onboarding, credit setup, or first-order delays, materials that can take a startup weeks to qualify are ordered the same day.

    public

    Global sourcing reach

    When a critical reagent, antibody, or animal model is backordered domestically, we source it through international suppliers we already work with, avoiding stalled studies and long lead times.

    savings

    Better pricing & terms

    Aggregated demand and long-standing supplier relationships secure volume pricing and favorable terms that a single early-stage buyer rarely obtains on their own.

    inventory_2

    Logistics & cold chain managed

    Quotes, POs, customs, cold-chain shipping, and receipt are coordinated end to end, removing the administrative load and the risk of compromised temperature-sensitive materials.

    verified_user

    Vetted, compliant suppliers

    We buy only from qualified, quality-checked vendors, reducing the risk of substandard reagents or models that would force costly repeat experiments.

    group_off

    No procurement headcount

    You avoid hiring or diverting staff to manage sourcing, vendor negotiation, and purchasing, that function comes built into the engagement.

    check_circleUS supplier network check_circleSelect international partners check_circleGlobal sourcing check_circleVetted & compliant vendors
    Free Introductory CallBack to Services
    Home / The Firm / Performance on Demand

    Performance on Demand

    Leverage the experience and skills of the Y Innovations specialized teams

    Our Performance on Demand packages offer a strategic advantage by bridging knowledge gaps, delivering expert insights tailored to your specific needs, and avoiding the traditional costs associated with a full, internal buildout. Streamline processes, optimize resource allocation, and implement solutions swiftly. Instead of rushing to hire, let us help you fill in the gaps until you are ready to bring the right person on board.

    Strategic advantage
    Choose your field:
    Hire right, because the penalties of hiring wrong are huge.Ray Dalio, Founder of Bridgewater Associates
    rocket_launch
    Package

    Start Up Package

    Everything a new venture needs to stand up operations quickly, legal scaffolding, research planning, and creative firepower, so you can move from formation to execution without a full internal buildout.

    Legal and Platform Package
    • Unlimited CDA review
    • Preclinical study critical path planning and developability OR investor deck drafting
    • Lab notebook and data management set up
    • Legal template package: financing term sheet, 1-page executive summary, SAFE, CDA
    Creative Package 1
    • Website development, including PhD scientists to help draft the website and web developers to build it
    Creative Package 2 Coming soon
    • Short form scientific explainer video
    gavel
    Package

    IP Packages

    Protect and build defensible value around your inventions, from a first patentability assessment through a full competitive-dominance strategy.

    IP Starter
    • Initial assessment of patentability, trademarkability, copyrightability
    • IP strategy planning
    IP Growth
    • One provisional patent application
    • Experimental planning strategy
    • Patentability assessment
    • Preliminary FTO assessment
    • Inventor assignments and recordation
    IP / Competitive Intelligence
    • Detailed competitive landscape
    • Patent and application landscaping
    • Technology landscaping
    • IP dominance strategy planning
    slideshow
    Package

    Presentation Packages

    Investor- and partner-ready narratives, originated or rebuilt, with the positioning and strategy behind every slide.

    Investor
    • (Pre-Seed to Series A) Investor deck origination or redraft, plus strategy
    Business Development
    • Business development deck origination or redraft, plus strategy
    precision_manufacturing
    Package

    CMC Packages

    De-risk your candidate’s path to manufacturing with expert CMC review and a clear-eyed developability assessment.

    Drug Candidate CMC Considerations
    • Review of drug substance and drug product entities
    • Strategy for starting and source material selection
    • Recommendations on manufacturing process and test methods
    • Defining specifications based on potential quality critical process parameters and attributes
    CMC Developability Assessment
    • Viable developability and risk profiling of your candidate: manufacturability, dosage form, formulation, stability and shelf-life, administration routes, bioavailability, patient compliance, toxicology and DMPK, specificity considerations
    fact_check
    Package

    Due Diligence Packages

    Rigorous scientific, technical, IP, and market evaluation for investors, calibrated to the stage of the opportunity.

    Early Stage (for Investors)
    • Pre-Seed and Seed scientific, technical, IP/legal, and market evaluation
    Late Stage (for Investors)
    • Clinical candidate assessment
    • IND/NDA/BLA diligence
    • Commercial market analysis
    • Litigation analysis
    badge
    Package

    Fractional C-Suite Packages

    Seasoned executive leadership on flexible, full- or part-time terms, exactly the seniority you need, exactly when you need it.

    Full or Part Time Fractional Experts
    • Chief Executive Officer
    • Chief Legal Officer / General Counsel
    • Chief Technical Officer
    • Chief Scientific Officer
    • Chief Development Officer
    experiment
    Package

    Research and Development Packages

    Move from concept to proof, pipeline strategy paired with hands-on in vitro and in vivo execution in your lab or ours.

    Pipeline Development
    • Analysis of technology
    • Analysis of potential competitors and competing technologies
    • Candidate selection
    • Indication selection
    In Vitro / In Vivo POC
    • Team of dedicated scientists to design and run experiments in your own lab, or a Y Innovations lab
    Case Studies
    biotech
    Fractional C-Suite · CSO

    Prioritizing a Preclinical Pipeline with the Clinic in Mind

    Case 01 / 03
    Engagement: Fractional, ongoing
    Cadence: ~2 days / week
    Client
    A Series A biotech with three overlapping programs, a lean team, and no senior scientific leader to arbitrate where limited capital and lab time should go.
    Challenge
    Bench momentum was outpacing strategy: experiments were being run because they were possible, not because they were decision-relevant, and the board wanted a defensible path to a lead program and IND.
    YI Solution
    A YI fractional Chief Scientific Officer stepped in ~2 days/week to set pipeline priorities with the clinical endpoint in view, redesigning the experimental plan around go/no-go decision points, sequencing in vitro and in vivo work to de-risk the eventual clinical hypothesis, and translating the science for the board and investors.
    What the CSO drove
    • flagLead-program selection and kill criteria
    • alt_routeDecision-driven experimental roadmap
    • timelinePreclinical-to-clinical translational plan
    • savingsReallocated budget away from low-signal work
    • groupsBoard and investor scientific narrative
    verified
    Outcome
    The company entered its next raise with one prioritized lead, a clear IND-directed plan, and months of runway preserved, senior scientific leadership applied exactly when strategy mattered most, without the cost or delay of a permanent CSO hire.
    gavel
    Fractional C-Suite · General Counsel

    IP & Contracts Function for a Scaling Startup

    Case 02 / 03
    Engagement: Fractional, 6 months
    Cadence: On-call + weekly
    Client
    A venture-backed platform company signing partnering deals and filing IP faster than its founders could manage without legal leadership.
    Challenge
    CDAs, collaboration terms, and inventorship were being handled ad hoc, creating risk around ownership, freedom to operate, and deal quality just as diligence pressure increased.
    YI Solution
    A YI fractional General Counsel / CLO built the legal and IP operating layer: a reusable contract template suite, an IP capture and filing cadence with outside counsel, and a deal-review process, while personally negotiating the near-term partnering agreements.
    What the GC drove
    • descriptionContract template & playbook suite
    • gavelIP capture, filing, and FTO cadence
    • handshakePartnering deal negotiation
    • fact_checkDiligence-ready legal record
    verified
    Outcome
    The company closed two partnerships on stronger terms and passed investor diligence cleanly, gaining a full legal function for the months it was needed rather than carrying a permanent executive salary too early.
    precision_manufacturing
    Fractional C-Suite · CTO / Head of CMC

    Manufacturing Readiness Ahead of a Raise

    Case 03 / 03
    Engagement: Fractional, 4 months
    Cadence: ~1.5 days / week
    Client
    A therapeutics startup with promising data but no in-house manufacturing or CMC leadership heading into a Series B.
    Challenge
    Investors were probing manufacturability and scale-up risk, and the team had no credible CMC story, process definition, or CDMO strategy to answer them.
    YI Solution
    A YI fractional CTO / Head of CMC defined the manufacturing strategy: assessed the process and materials, ran a CDMO capability evaluation and selection, and built the CMC risk profile and scale-up roadmap that anchored the technical diligence.
    What the CTO drove
    • architectureProcess definition & materials strategy
    • local_shippingCDMO evaluation and selection
    • shieldCMC risk profile and mitigations
    • trending_upScale-up roadmap for diligence
    verified
    Outcome
    The company walked into its Series B with a credible manufacturing narrative and a selected CDMO partner, converting a diligence weakness into a strength, delivered by senior CMC leadership engaged only for the pre-raise window.
    The Cost Case
    biotech
    Fractional CSO

    CSO: In-House vs. Fractional

    Model 01 / 03
    Basis: 12 months
    ~2 days / week
    Cost for the engagement
    $450,000 $180,000 In-house YI Fractional
    In-house$450,000
    YI fractional$180,000
    You save$270,000 · 60%
    Cumulative savings over the engagement
    $270,000 saved Month 1 Month 12

    infoBase ~$350K + ~30% bonus/benefits for a full-time CSO; equity dilution and severance would add further in-house cost.

    gavel
    Fractional General Counsel

    General Counsel: In-House vs. Fractional

    Model 02 / 03
    Basis: 6 months
    On-call + weekly
    Cost for the engagement
    $475,000 $150,000 In-house YI Fractional
    In-house$475,000
    YI fractional$150,000
    You save$325,000 · 68%
    Cumulative savings over the engagement
    $325,000 saved Month 1 Month 6

    infoFull-time biotech GC loaded at ~$475K/yr; a permanent hire also carries recruiting, benefits, and ramp-up time.

    precision_manufacturing
    Fractional CTO / Head of CMC

    CTO / CMC: In-House vs. Fractional

    Model 03 / 03
    Basis: 4 months
    ~1.5 days / week
    Cost for the engagement
    $133,200 $48,000 In-house YI Fractional
    In-house$133,200
    YI fractional$48,000
    You save$85,200 · 64%
    Cumulative savings over the engagement
    $85,200 saved Month 1 Month 4

    infoFull-time CTO/Head of CMC loaded at ~$400K/yr; fractional avoids a permanent salary for a time-boxed, pre-raise need.

    Illustrative estimates for US venture-backed biotech in loaded cash terms (base salary plus bonus and benefits). Figures exclude equity dilution, recruiting fees, and severance, which increase the true cost of a full-time hire. Actual costs vary by stage, location, and scope.

    Book an Intake Call NowBack to Services
    Home / The Firm / Thought Articles

    Thought Articles

    Bite-sized and highly digestible

    A series of posts to provide bite-sized and highly digestible snippets of information to get you thinking about issues that may affect your company's operations, research, development, and the implementation and commercialization of your products.

    policySeries · No. 01

    The AI Policy Race

    Our first post in the series: what the race to regulate artificial intelligence means for builders and boards.

    smart_toyAI & Policyschedule4 min read
    Read →
    auto_storiesOngoing

    More coming soon

    New articles publish through the Y Innovations newsletter and LinkedIn. Subscribe below to stay up to date.

    calendar_monthNew articles monthlyrss_feedNewsletter + LinkedIn
    Subscribe →
    Subscribe to the newsletterBack to The Firm
    Home / The Firm / News and Events

    News and Events

    rocket_launchAnnouncement

    Y Innovations Group Expands Ecosystem with Yung Ventures and Y Innovations Studios

    YI Group announces the official launch of the Y Innovations Studios and Yung Ventures, our early-stage venture studios and VC firm, seeking to redefine efficient and effective company building by bridging the gap between capital investment and experienced operational and strategic support.

    trending_upYung VenturesscienceThe Studios
    Read →
    Subscribe to the newsletterReturn to the helix
    Capital & Strategy · Yung Ventures

    Combining expertise in science and technology with strong operational execution.

    Yung Ventures pursues high-conviction, thesis-driven investments across life sciences and the energy transition, applying deep regulatory, IP, and commercial expertise across every stage and five strategic regions.

    Apply to be an Innovation
    The Yung Ventures Thesis

    Durable returns are generated at the intersection of science, urgency, and commercial clarity.

    We back platforms over single assets, evidence over speculation, and teams who understand how novel technology reaches the people and systems that need it. Yung Ventures invests through two distinct theses, each with its own criteria, indications, and regional playbooks.

    01 · Differentiation

    Real novelty

    Novel mechanisms, platforms, and modalities with clear IP moats, or step-change improvements in performance, cost, and scalability. We avoid incremental reformulations and me-too approaches.

    02 · Urgency

    Material need

    Indications with high unmet need and regulatory momentum, and use cases where the value to customers is quantifiable and significant.

    03 · Clarity

    Path to market

    A defined route to adoption, whether through reimbursement and partnering in life sciences or supportive policy, falling costs, and customer demand in energy.

    Two distinct theses

    Choose a path.

    Life Sciences

    biotechFrom molecule to market

    Therapeutics, medical devices, diagnostics, and health technology, from mRNA and cell therapy to multi-cancer early detection and AI-native drug discovery. Platform-first, stage-aware, biomarker-driven.

    • Therapeutics: mRNA, cell therapy, antibodies and ADCs, gene editing
    • Diagnostics: liquid biopsy MCED, precision and companion diagnostics
    • Health tech: AI drug discovery, digital health infrastructure
    Energy

    boltPowering the transition

    High-growth energy efficiency and renewable businesses that deliver meaningful decarbonization, strong unit economics, and scalable platforms across the buildings, industry, mobility, and grid layers.

    • Products: advanced heat pumps, next-gen solar, storage systems
    • Platforms: grid orchestration, energy management, analytics
    • Developers: distributed renewables, retrofits, industrial decarbonization
    Yung Ventures

    Building the reality of technology.

    Pitch us, or add your company to our investor lists. We invest where deep science meets a team that can carry it to market.

    Pitch us Return to the helix
    Home / The Studios

    Y Innovations Studios

    A uniquely competitive venture studio

    Y Innovations presents: The Studios, a uniquely competitive venture studio that provides the necessary tools and partnerships critical to the long-term success of our Innovations.

    Built on our extensive industry experience and network, the Studios seeks to provide a roadmap to success by facilitating funding, sponsorships, strategic advice from industry experts, exclusive discounts for professional services, and much more.

    Build with Y Innovations Studios.

    Each Studio carries its own name, its own region, and a distinct focus and set of competitive advantages we look for in the Innovations we back.

    Cortex, the United States Studio campus
    Cortex Studios

    United States

    The United States remains the deepest capital market and the largest single commercial market for therapeutics, medical devices, and energy technology. A clearly defined regulatory pathway, whether at the FDA or across federal and state energy programs, converts technical progress into financeable milestones, which is what allows a company to raise on evidence rather than on narrative. A US entity is also the structure most acquirers, licensors, and cross-border investors expect, and we use that footing to take life science and energy companies into markets beyond their own.

    Focus
    • arrow_rightPrecision oncology, cell and gene therapy, and rare disease programs
    • arrow_rightAI-enabled drug discovery and diagnostics with a defensible data position
    • arrow_rightMedical devices and diagnostics with a defined FDA pathway
    • arrow_rightEnergy storage, grid technology, and clean-energy hardware
    Competitive advantages
    • checkProximity to the Boston, Cambridge, and Bay Area research clusters and their talent pools
    • checkThe deepest concentration of specialist life science and deep-tech investors
    • checkIn-house regulatory, reimbursement, and IP consulting
    • checkAccess to academic core facilities, contract research partners, and clinical sites
    Gateway, the China Studio campus
    Gateway Studios

    China

    China has become a genuine source of global assets rather than a manufacturing endpoint. Building and validating here compresses both the cost and the calendar of the earliest, most capital-hungry stage of a company’s life. That value is only realised if the rights are clean, so we structure ownership, data provenance, and filings for a cross-border transaction from day one.

    Focus
    • arrow_rightTherapeutics: antibody-drug conjugates, biologics, and small molecules
    • arrow_rightBatteries, energy storage, and renewable generation
    • arrow_rightAdvanced materials and the equipment that manufactures them
    • arrow_rightAssets built for out-licensing into Western markets
    Competitive advantages
    • checkSpeed and cost of preclinical and early clinical development relative to Western programs
    • checkUnmatched manufacturing and supply-chain density, from bench scale to commercial
    • checkEstablished contract research and contract manufacturing networks on the ground
    • checkIP structured from the outset to ring-fence Western rights ahead of any licensing conversation
    Launchpad, the Europe / UK Studio campus
    Launchpad Studios

    Europe

    Europe is where capital efficiency is a genuine advantage. Grant and programme funding extends runway without dilution, and a lower cost base means the same round buys materially more evidence. We build toward a dual EMA and FDA strategy from the first protocol, so a European company is never rebuilt later to be credible to American investors and partners.

    Focus
    • arrow_rightAdvanced therapy medicinal products, gene therapy, and rare disease
    • arrow_rightHealth data engines, AI diagnostics, and clinical decision support
    • arrow_rightRenewables, grid technology, and industrial decarbonisation
    • arrow_rightUniversity spin-outs with strong science and thin commercial infrastructure
    Competitive advantages
    • checkA harmonised EMA pathway reaching a single large market from one regulatory strategy
    • checkSubstantial non-dilutive funding available through national and EU-level programmes
    • checkA world-class academic spin-out pipeline and lower operating burn than US equivalents
    • checkPolicy tailwinds behind decarbonisation and health-system modernisation
    Ithra, the Saudi Arabia Studio campus
    Ithra Studios

    Saudi Arabia

    The Kingdom is deliberately building a domestic life sciences base, and it rewards companies that build with it rather than sell into it. An in-Kingdom footprint turns a localisation requirement into a commercial advantage. Regional health systems are buyers as well as regulators, which gives an early company something rare: a credible path to revenue running alongside its clinical plan.

    Focus
    • arrow_rightBiotech and medtech built in the Kingdom and scaled outward
    • arrow_rightBiosimilar, vaccine, and sterile manufacturing capacity
    • arrow_rightGenomics and clinical research infrastructure
    • arrow_rightLocalisation of health supply chains across the Gulf and wider MENA region
    Competitive advantages
    • checkAlignment with Vision 2030 priorities, and the institutional co-investment appetite that follows it
    • checkIncentives and procurement preference for companies that manufacture and employ in-Kingdom
    • checkNewly built research, laboratory, and manufacturing infrastructure
    • checkA single footprint that opens regional distribution across the Gulf and wider MENA
    Local Roots, Global Reach

    Access to regional resources.

    A Y Innovations Studio lab overlooking its campus
    factory

    Local Manufacturing

    Direct pathways to regional manufacturing partners so products can be made close to market.

    biotech

    Contract Research Labs

    Local contract research laboratory services to run studies without leaving the region.

    local_shipping

    Logistics Services

    On-the-ground logistics support for supply, distribution, and operations.

    verified_user

    IP Generation & Protection

    Support for generating, filing, and protecting the intellectual property behind your science.

    The Offer

    Everything a founder needs to thrive.

    payments

    Up to $150,000 Grant

    A grant of up to $150,000 to your company for legal services through Y Innovations, excluding intellectual property services.

    meeting_room

    Lab & Office Space

    Bench seats and office desks to build from day one.

    account_tree

    SPV Formation

    The Studios form, manage, and operate a special purpose vehicle through which investors can fund your open round.

    handshake

    Investment Facilitation

    Facilitated meetings with angel investors, venture capital firms, and funding institutions. The Studios may also co-invest in your rounds.

    public

    US Entity, On Us

    Upon acceptance, the Studio covers the cost of registering your entity in the United States, a footing in the world’s largest life science market from day one.

    hub

    Support Services

    A network of industry partners at favorable rates: banks, corporate facilitators into the US, China, and the Middle East, and real estate.

    This is a summary only. Additional Terms and Conditions Apply.

    Who We Back

    Founders who built local with opportunities to expand global.

    Ithra biotech laboratory in Saudi Arabia Renewable energy laboratory with solar photovoltaic, battery, and electrolyzer testing

    Start your application.

    Apply directly with a concise overview of your solution, traction, and roadmap.

    Apply now

    operations@y-innovations.com  ·  Accepted companies onboard into the Studios in Boston, London, Shanghai, or Riyadh.

    Boston · Cambridge · San Francisco · London · Shanghai · Riyadh
    Build with usReturn to the helix
    Home / Yung Family Office

    Yung Family Office

    Quiet, long-horizon stewardship

    The family office manages capital across generations with the same discipline the group brings to science.

    Direct and Co-Investments

    Selective direct positions, often alongside Yung Ventures, where the family's horizon is the advantage.

    Governance and Succession

    Structures, education, and counsel that keep purpose and capital aligned across generations.

    Philanthropy

    Giving with the same rigor as investing, focused where science can change outcomes.

    Mandate

    Yung Family Office will back frontier technologies that measurably improve the wellbeing and resilience of life on Earth.

    Mission and core belief

    bolt

    Capital is deployed as a lever to accelerate technologies that expand flourishing for all sentient beings and the biosphere, not just human shareholders.

    hourglass_top

    The office embraces patient, long-duration capital, matching multi-decade scientific and infrastructure timelines rather than short fund cycles.

    verified

    Investments must combine clear scientific or technical merit, scalable business models, and positive, measurable environmental or social impact.

    Strategic themes

    rocket_launch

    Space, Planetary Defense, and Off-World Infrastructure

    • arrow_rightEnabling technologies for orbital and cislunar infrastructure: satellites, in-space manufacturing, earth observation, and space systems that improve life on Earth through climate monitoring, precision agriculture, and disaster response.
    • arrow_rightPlatforms that make space more accessible and sustainable: launch, in-orbit servicing, debris mitigation, and autonomous operations, with strong regulatory and safety frameworks.
    • arrow_rightA preference for companies whose space capabilities directly enhance planetary resilience, biodiversity protection, and climate-risk management, such as high-resolution environmental data services.
    pets

    Animal Longevity, Welfare, and Multi-Species Health

    • arrow_rightHealth-tech, biotech, and data platforms that extend healthy lifespans and improve quality of life across species, from companion animals to livestock and wildlife, rather than purely cosmetic human anti-aging.
    • arrow_rightPrecision medicine, genomics, wearables, and Internet-of-Medical-Things architectures adapted for animals, enabling continuous monitoring, early interventions, and welfare optimization.
    • arrow_rightResearch tools and platforms such as comparative genomics and microbiome and metabolome analytics that unlock cross-species insights and reduce animal suffering in agriculture, research, and urban environments.
    eco

    Regenerative Infrastructure and Climate-Positive Systems

    • arrow_rightClimate-tech and sustainable infrastructure that repair and regenerate ecosystems: low-carbon energy systems, water management, climate-resilient materials, and nature-based solutions.
    • arrow_rightMulti-benefit infrastructure that delivers resilient services across energy, water, and mobility while improving biodiversity, reducing pollution, and strengthening local communities.
    • arrow_rightPlatforms that digitize and optimize infrastructure through AI, sensing, and automation to reduce resource use and emissions, coupled with strong compliance and governance.
    clinical_notes

    Health Tech and Life Sciences Across Species

    • arrow_rightCore focus areas given their alignment with long-term societal and planetary needs and their suitability for patient capital.
    • arrow_rightTechnologies that solve urgent, scalable health challenges such as chronic disease management, aging, and zoonotic risk, through rigorous clinical or veterinary evidence and regulatory readiness.
    • arrow_rightPlatforms such as AI-driven diagnostics, genomic analysis, and biomarker discovery that produce actionable data for human and animal caregivers, improving outcomes at population scale.

    Investment style and structure

    insightsImpact and measurement

    All investments must articulate an impact thesis with explicit, measurable environmental or social outcomes alongside financial return, consistent with emerging impact-investing norms.

    Impact metrics track cross-species welfare, such as avoided animal suffering and improved habitat, planetary resilience, such as emissions avoided and water saved, and equity of access, such as availability of services beyond wealthy human populations.

    The office avoids hype-driven sectors and instead brings the shovels and buckets: picks-and-shovels infrastructure that enables sustainable booms rather than speculative bubbles.

    Legacy and Narrative

    Yung Family Office views its capital as part of a multi-generational stewardship mandate: to leave a planet that is more livable, biodiverse, and resilient for all life. Philanthropy and investment are treated as complementary tools, philanthropy can de-risk early science or policy work, while investments scale the solutions that prove viable.

    We invest where science, infrastructure, and ethics intersect to expand the circle of care beyond humans, and we measure success in lives improved, habitats restored, and futures protected.Megan Yung

    Speak with the officeReturn to the helix
    Home / About / Join Us

    Join Us at Y Innovations

    The Y Innovations Group leverages strategic consulting, start-up incubation, and venture capital. We believe the highest performing teams include people from a wide variety of backgrounds and experiences, and we strive to build an open, diverse, and inclusive culture for all of our members. We understand that the job description may not always match the best candidates, so we encourage you to apply if you think you would be a good fit for the role.

    To apply, please send your CV to operations@y-innovations.com and follow the Y Innovations LinkedIn page for updates on our company and exciting news.

    Open Positions
    biotech
    Advisory and Consulting · Life Sciences

    Patent Agent (Life Sciences)

    Entity: Yung Innovations PLLC
    Location: Cambridge, MA
    Type: Full-time
    Overview
    Yung Innovations PLLC, the consulting and advisory arm of Y Innovations, is looking for a patent agent (life sciences) with experience in small molecules, cell therapy, and gene therapy patent applications. The Patent Agent will work with our intellectual property attorneys to draft and prosecute patent applications, collaborating with various departments in our early-stage incubator, including R&D and search and evaluation.
    Responsibilities
    • check_circlePreparing patent applications for filing with the USPTO
    • check_circleAssisting with the prosecution of patent applications, worldwide
    • check_circleEvaluating discoveries and preparing invention disclosure forms
    • check_circleTriage of content relevant to information disclosure statements
    • check_circlePerforming patent searches and evaluating results
    • check_circleProviding technical assistance on various IP projects, as needed
    Qualifications
    • schoolAt least three (3+) years of legal practice experience, preferably at a law firm
    • schoolPhD or MD in organic chemistry, medicinal chemistry, immunology, molecular biology, cell biology, microbiology, oncology, or a related field. Post-doctoral experience desirable but not required
    • schoolUSPTO registration number required
    • schoolSuperior academic credentials; excellent oral, written, and interpersonal skills
    memory
    Advisory and Consulting · AI, ME, EE

    Patent Agent (AI, ME, EE)

    Entity: Yung Innovations PLLC
    Track: Of Counsel / Partner
    Type: Full-time
    Overview
    Yung Innovations PLLC is looking for a patent agent (AI, ME, EE / Of Counsel / Partner) with experience in one or more of: artificial intelligence, enterprise and mobile applications, databases, web and cloud services, operating systems, software user interfaces, open source, 3D graphics, grid computing, networking, telecommunications, network protocols, IEEE standards, or network security patent applications. This role collaborates with various departments in our early-stage incubator, including R&D and search and evaluation.
    Responsibilities
    • check_circlePreparing patent applications for filing with the USPTO
    • check_circleAssisting with the prosecution of patent applications, worldwide
    • check_circleEvaluating discoveries and preparing invention disclosure forms
    • check_circleTriage of content relevant to information disclosure statements
    • check_circlePerforming patent searches and evaluating results
    • check_circleProviding technical assistance on various IP projects, as needed
    Qualifications
    • schoolAt least three (3+) years of legal practice experience, preferably at a law firm
    • schoolMinimum BS in Computer Science, Computer Engineering, Electrical Engineering, or possibly Physics. Prior engineering experience is a plus
    • schoolUSPTO registration number required
    • schoolSuperior academic credentials; excellent oral, written, and interpersonal skills
    gavel
    Advisory and Consulting · Legal

    Of Counsel / Partner (Legal)

    Focus: Transactions
    and/or Prosecution
    Type: Flexible
    Overview
    If you have a portable book that makes you partially or fully self-sustaining, this could be an incredible opportunity to leverage the Y Innovations platform to integrate your existing portfolio of clients and bolster your practice.
    Why Y Innovations
    • check_circleIntegrate your existing clients onto an established, integrated platform
    • check_circleAccess an early-stage incubator pipeline and cross-disciplinary teams
    • check_circleGrow your practice alongside R&D, search and evaluation, and IP specialists
    At a glance
    • workspace_premiumEngagement: Of Counsel or Partner
    • balancePractice: Transactions and/or Prosecution
    • mailApply: operations@y-innovations.com
    Open Positions
    insights
    Innovations Studios · Search and Evaluation

    Senior Associates (Search and Evaluation)

    Entity: Y Innovations Studios LLC
    Teams: Life Sciences, AI/ME/EE, Energy
    Type: Full-time
    Overview
    Y Innovations Studios LLC (the “Studios”) is looking for Senior Associates for its life sciences, AI/ME/EE, and energy search and evaluation teams. These roles work closely with management, including the CEO and CIO, and collaborate with various departments in the Studios, including R&D and consultants from Yung Innovations PLLC on intellectual property matters. Senior Associates in our search and evaluation teams are important members of our organization and provide critical support to the Studios pipeline of early-stage companies.
    Responsibilities
    • check_circleReview applications and work closely with management to identify relevant early-stage companies that may be a good fit for the Studios
    • check_circleLead due diligence for evaluation of early-stage companies: technical assessment, comparison, and ranking
    • check_circleAssess intellectual property competitiveness, market review, and industry analyses
    • check_circleManage recruitment and selection of portfolio startups
    Qualifications
    • schoolAt least 3 years of industry experience in a competitive incubator or venture firm, biotechnology company, software company, energy company, or engineering company
    • schoolEducational background depends on team; for the life sciences search and evaluation team, an advanced graduate degree (MD or PhD) is required
    diversity_3
    Innovations Studios · Advisory

    Studios Advisor

    Entity: Y Innovations Studios LLC
    Type: Flexible
    Apply: ali.yung@y-innovations.com
    Overview
    Join our team of accomplished Advisors. If you have a passion for advising start-up companies and are looking for a flexible opportunity to work with innovative founders on cutting-edge technology, please send your application directly to ali.yung@y-innovations.com. Some of our current companies are focused in the sectors listed alongside, and more.
    Current focus sectors
    • scienceCell therapy manufacturing: dramatically reducing manufacturing time for certain cell therapy candidates
    • medicationSmall molecule: novel pathways and targets
    • experimentHigh-throughput compound screening: increased efficiency and reduced costs
    • biotechRNA and delivery technology: focusing on Alzheimer’s Disease
    • boltAI platform for home energy efficiency: potential to expand into commercial
    • clinical_notesAI platform for efficient clinical trial management
    Apply nowReturn to the helix
    Home / About / Contact

    Contact

    Reach us directly

    operations@y-innovations.com

    Not sure what you need or just want to explore options with a Partner? Book a free introductory call and we would be happy to guide you.

    Free Introductory Call

    Or write to us

    Return to the helix
    Home / Terms of Use

    Terms of Use

    Effective: July 25, 2024
    Return to the helix
    Home / Privacy Policy

    Privacy Policy

    This Privacy Policy was last updated on July 25, 2024
    Return to the helix